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Abstract
Background: Ameloblastoma is a rare benign odontogenic tumor with locally aggressive behavior and a high
recurrence rate. When metastases occur, which are uncommon, lungs constitute the most frequent site involved.
Malignant ameloblastomas are different from ameloblastic carcinomas. Malignant ameloblastomas are tumors
considered metastatic despite the appearance of well-differentiated or benign histology, while ameloblastic
carcinomas are histologically malignant in both primary and metastatic sites.
Case presentation: A 24-year-old Moroccan man presented a malignant ameloblastoma of the mandible. The
tumor was entirely resected. Five years later, a local recurrence occurred. Our patient was treated by exclusive
radiotherapy with persistence of a residual disease. After two years he developed multiple lung metastases. Our
patient received a combination chemotherapy using doxorubicin and cisplatin.
Conclusion: Less than 50 cases of ameloblastoma with metastases have been reported. There is still no standard
treatment for metastatic ameloblastoma. Only through continuous reporting of such cases will clinicians be able to
draw an optimal strategy for management of this pathology.
Introduction
Ameloblastoma, from the English word “amel” which
means enamel and the Greek word “blastos” which
means germ [1], is a rare entity of benign odontogenic
tumor. It arises from the epithelium of the dental lamina
and it is known by its local aggressive behavior and the
high recurrence rate [2].
Ameloblastoma was first described in 1827 by Cusack
[3]. In 1885, Malassez introduced the name “adamanti-
noma”, which is now used to describe a rare form of bone
cancer described by Fisher in 1913 [4]. It was renamed to
its current denomination by Churchill in 1930 [5].
In the recent WHO classification, a distinction was
made between ameloblastoma, malignant ameloblastoma
and ameloblastic carcinoma [2]. Malignant ameloblastoma
differs from ameloblastoma due to the presence of metas-
tases. They both have the same benign histology [6].
Ameloblastic carcinoma has malignant cytologic features
regardless of the presence of metastases. In ameloblas-
toma, metastases are uncommon. When they occur, lungs
are involved in over 80% of cases [7].
Localized disease is treated by radical surgery. How-
ever, in metastatic settings, chemotherapy remains the
only choice of treatment. Unfortunately, results are
unpredictable. We report below a case of an ameloblas-
toma with metastatic evolution five years after initial
surgical treatment.
Case report
A 24-year-old Moroccan man presented in 2000 with a
mass of the right mandible. A panoramic radiograph
revealed a multilocular radiolucency, requiring a biopsy. A
histopathological examination of the specimen showed a
well-differentiated neoplastic proliferation. This appeared
as strands of peripheral columnar cells in palisading orien-
tation. The fibroblastic tumor-associated stroma was dense
with collagen fibers and highly infiltrated by inflammatory
mononuclear cells. No histological signs of malignancy
* Correspondence: mounia.amzerin@gmail.com
1Department of Medical Oncology, National Institute of Oncology, Rabat,
Morocco
Full list of author information is available at the end of the article
Amzerin et al. Journal of Medical Case Reports 2011, 5:491
http://www.jmedicalcasereports.com/content/5/1/491 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Amzerin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.were observed (Figure 1). The diagnosis of ameloblastoma
was confirmed. Treatment consisted of hemimandibulect-
omy. Surgical margins were free of tumor. Five years later,
the lesion recurred as a mass of his right jaw. The recur-
rence was confirmed by a second biopsy. At the same time,
a chest tomography revealed three metastatic nodules of
lungs. Our patient received exclusive radiotherapy for the
jaw mass, at the dose of 60 Gy. No treatment was delivered
for the lung metastases. The disease was controlled for two
years, until our patient presented again with a right sub-
mandibular mass and multiple bilateral lung metastases
(Figure 2A). Our patient received combination chemother-
apy using doxorubicin 50 mg/m
2 and cisplatin 100 mg/m
2.
The assessment of response to chemotherapy was made
after two cycles. The pain disappeared, and tomography
showed, according to RECIST criteria, local stabilization
and partial response of the lung lesions (30%) (Figure 2B).
The response was maintained after six cycles of
chemotherapy.
Discussion
Odontogenic neoplasms are rare tumors of the oral cav-
ity. Among these, ameloblastoma is the second most
common entity after odontoma [2]. Ameloblastoma and
metastatic ameloblastoma are different. According to
the recent WHO classification, ameloblastoma is a loca-
lized benign disease whereas malignant ameloblastoma
is considered metastatic despite the appearance of well
differentiated or benign histology. Ameloblastic carci-
noma shows malignant features in both primary and
metastatic sites [6].
The average age at diagnosis of patients with amelo-
blastoma is 34 years with a range of five to 74 years [8].
Men and women are equally affected. The most fre-
quent primary site is the angle of the mandible.
There are several histological subtypes, including
plexiform, follicular, acanthomatous, basaloid, granular
cell, cystic and desmoplastic forms. So far, the natural
course of the disease can not be predicted. The follicular
entity is the most common [2]. Basic symptoms are a
swelling mass, pain and fistula in the palate [9].
Ameloblastoma is described as a slowly growing,
locally invasive benign tumor with a high propensity for
local recurrence. There is a 50% to 72% incidence of
local recurrence after initial therapy [7]. Radical surgery
remains the mainstay of therapy. This is often difficult
Figure 1 Histopathologic features of ameloblastoma.
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region. In case of incomplete resection, radiotherapy can
be considered as an adjuvant measure.
Metastases are uncommon, which is why metastatic
ameloblastoma is considered benign (in addition to the
benign features on histology). They generally occur after
an interval ranging from 10 to 12 years [8]. Lungs are
involved in 75% to 80% of cases. Other sites may also be
involved, such as regional lymph nodes, pleura, vertebra,
skull, diaphragm, liver and parotid glands [6]. Many fac-
tors have been associated with the tendency to develop
metastases, including extent of initial disease, multiple
surgeries or radiation therapy [6-8]. Several theories have
been suggested to explain metastatic spread, relating
to lymphatic or hematogenous causes, aspiration or
heterotopia [10].
The treatment for metastatic ameloblastoma remains
delusive. When metastases are removable, surgery is the
treatment of choice. Results of radiotherapy and/or che-
motherapy are unpredictable and the data are poor. Less
than 50 cases were reported and conclusions are dispa-
rate (Table 1). Gall tested cyclophosphamide and
methotrexate 5-fluorouracil therapy in a patient with
lung metastases that occurred nine years after initial
therapy. He noticed that the functional outcome was
good although no objective response was seen [11].
Ramadas obtained partial response after 13 cycles of
combination chemotherapy-associating cisplatin and
cyclophosphamide administrated for lung metastases
[12]. Some other therapies have also shown activity,
including vinblastine, bleomycin, paclitaxel and carbo-
platin [9-13].
A review of the literature made by Lanham concluded
that chemotherapy failed to show any antitumoral activity,
including doxorubicin, methotrexate, prednisolone, bleo-
mycin, 5-fluorouracil and dacarbazin [14]. Moreover, the
literature reports some patients with metastases showing
long survival without receiving chemotherapy [6,15].
Our case illustrates the natural course of the disease. In
spite of radical surgery, lesions recurred. The metastases
were asymptomatic. They were discovered during a clas-
sical work-up. Our finding, concerning response to dox-
orubicin-cisplatin, is adding to the published evidence
that platinum chemotherapy is active in metastatic
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Figure 2 Presenting symptoms two years after radiothereapy. (A) Before chemotherapy 1 - right submandibular mass with endocranial
extension, sphenoidal lysis and infiltration of the hemitongue; 2 - multiple lung metastases. (B) After two cycles of chemotherapy. 1 - local
stabilization; 2 - partial response.
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Page 3 of 5Table 1 Published data concerning chemotherapy regimens used in metastatic ameloblastoma
Publication details Regimen Results Reference
CR Cycolphosphamide Good functional [11]
-M Methotrexate outcome
-Lung metastases 5 Fluorouracil OR: 0%
CR Vinblastine Partial response: 50% [13]
-M Cisplatin
-Lung metastases Bleomycin
CR Adriamycin Partial response [12]
-W, 17 years old Cisplatin
-Lung metastases Cyclophosphamide
CR 1
st line: 5FU-Cisplatin Progression disease after two cycles; repetitive partial response. [9]
-W, 28 years old 2
nd line: Paclitaxel-
-Lung metastases Carboplatin
CR Cyclophosphamide OR: 0% [17]
-M, 46 years old
-Lung metastases + mediastinal adenopathies
CR No chemotherapy Stable disease during 18 months [6]
-M, 55 years old
-Lung metastases
CR No chemotherapy; surgery for removable metastases. Survival: 54 years [15]
-W, 39 years old
-Lung metastases
Review Doxorubicin ± 5FU. OR: 0%. [14]
Outcome of chemotherapy in metastatic ameloblastoma. Methotrexate ± cyclophosphamide
Blemomycin
5FU-Cisplatin
Vincristine
Prednisolone
CR: case report; M: man; W: woman; OR: objective response.
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5ameloblastoma. Moreover, even though no objective
response is seen, data show that chemotherapy improves
clinical symptoms [6].
There are too few cases of metastatic ameloblastoma to
consider randomized trials. Platinum-based regimens
could be proposed as a first line treatment. Another path-
way to explore is epidermal growth factor receptor
(EGFR)-targeting. Ameloblastoma is a tumor originating
from EGFR-expressing odontogenic epithelium, with
expression levels ranging from 0% to 100% in some studies
[16].
Conclusion
Despite the slowly growing nature of ameloblastoma,
endocranial extension and/or occurrence of metastases
cause pain and affect survival.
In metastatic ameloblastoma, results are unpredictable.
Surgery, when feasible, remains the mainstay of therapy.
There is no sufficient data to support or reject the use
of chemotherapy. The expression of EGFR by odonto-
genic tumors could be an interesting approach to
explore.
Consent
Written informed consent was obtained from our
patient for publication of this case report and any
accompanying images.
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